174 related articles for article (PubMed ID: 38280007)
21. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
22. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways.
Kato H; Karube K; Yamamoto K; Takizawa J; Tsuzuki S; Yatabe Y; Kanda T; Katayama M; Ozawa Y; Ishitsuka K; Okamoto M; Kinoshita T; Ohshima K; Nakamura S; Morishima Y; Seto M
Cancer Sci; 2014 May; 105(5):537-44. PubMed ID: 24581222
[TBL] [Abstract][Full Text] [Related]
24. An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified.
Hoffmann JC; Chisholm KM; Cherry A; Chen J; Arber DA; Natkunam Y; Warnke RA; Ohgami RS
Hum Pathol; 2016 Feb; 48():9-17. PubMed ID: 26772393
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus-specific CD8(+) T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired.
Cárdenas D; Vélez G; Orfao A; Herrera MV; Solano J; Olaya M; Uribe AM; Saavedra C; Duarte M; Rodríguez M; López M; Fiorentino S; Quijano S
Clin Exp Immunol; 2015 Nov; 182(2):173-83. PubMed ID: 26174440
[TBL] [Abstract][Full Text] [Related]
26. Genetic and immunohistochemical characterization of Epstein-Barr virus-associated diffuse large B-cell lymphoma.
Al-Humood S; Alqallaf A; Al-Shemmari S; Al-Faris L; Al-Ayadhy B
Acta Haematol; 2014; 131(1):1-10. PubMed ID: 24008861
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression.
Jiang XN; Yu BH; Yan WH; Lee J; Zhou XY; Li XQ
Oncoimmunology; 2020; 9(1):1683346. PubMed ID: 32002294
[No Abstract] [Full Text] [Related]
28. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
29. Diffuse large B-cell lymphoma in a South African cohort with a high HIV prevalence: an analysis by cell-of-origin, Epstein-Barr virus infection and survival.
Cassim S; Antel K; Chetty DR; Oosthuizen J; Opie J; Mohamed Z; Verburgh E
Pathology; 2020 Jun; 52(4):453-459. PubMed ID: 32305135
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: Is It Different between Over and Under 50 Years of Age?
Monabati A; Vahedi A; Safaei A; Noori S; Mokhtari M; Vahedi L; Zamani M
Asian Pac J Cancer Prev; 2016; 17(4):2285-9. PubMed ID: 27221931
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.
Ayoubian H; Ludwig N; Fehlmann T; Menegatti J; Gröger L; Anastasiadou E; Trivedi P; Keller A; Meese E; Grässer FA
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429351
[TBL] [Abstract][Full Text] [Related]
32. The presence of Epstein-Barr virus (EBV) in diffuse large B-cell lymphomas (DLBCLs) in Turkey: special emphasis on 'EBV-positive DLBCL of the elderly'.
Uner A; Akyurek N; Saglam A; Abdullazade S; Uzum N; Onder S; Barista I; Benekli M
APMIS; 2011 Apr; 119(4-5):309-16. PubMed ID: 21492232
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological analysis of neoplastic PD-L1-positive EBV
Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
[TBL] [Abstract][Full Text] [Related]
34. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
Witte HM; Merz H; Biersack H; Bernard V; Riecke A; Gebauer J; Lehnert H; von Bubnoff N; Feller AC; Gebauer N
Br J Haematol; 2020 Apr; 189(2):257-268. PubMed ID: 31958882
[TBL] [Abstract][Full Text] [Related]
35. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.
Castillo JJ; Beltran BE; Miranda RN; Young KH; Chavez JC; Sotomayor EM
Am J Hematol; 2018 Jul; 93(7):953-962. PubMed ID: 29984868
[TBL] [Abstract][Full Text] [Related]
36. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time.
Chang ST; Lu YH; Lu CL; Weng SF; Lin SH; Kuo SY; Chuang YT; Takeuchi K; Ohshima K; Chuang SS
J Clin Pathol; 2014 Apr; 67(4):326-32. PubMed ID: 24218026
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
[TBL] [Abstract][Full Text] [Related]
39. [ALK-positive large B-cell lymphoma with EBV infection or cyclin D1 expression: a clinicopathological analysis of 3 cases].
Wu WN; Xiang CX; Ma DS; Liu GZ; Liu H
Zhonghua Bing Li Xue Za Zhi; 2022 Jun; 51(6):506-511. PubMed ID: 35673721
[No Abstract] [Full Text] [Related]
40. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, in the Oral Cavity.
Costa SFDS; Silva AMB; Amaral-Silva GK; Pontes HAR; Pontes FSC; Fonseca FP; Almeida OP
J Craniofac Surg; 2019; 30(3):e259-e262. PubMed ID: 31048622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
